← 홈

Antibody · HER2

71개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-13 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 71개
AntibodyAHotBristol Myers SquibbdeliveryPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 75%임상시험 431상태 ACTIVE
AntibodyCHotRocheDM1) and trastuzumab deruxt…Phase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 224상태 DISCONTINUED
AntibodyBHotInnoventvedotin (an HER2-targeted a…Phase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 4.5%임상시험 123상태 RECRUITING
AntibodyCstaleJiangsu HengruiPhase 2

Camrelizumab (Camrelizumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase2#인기#항체+5
임상시험 78상태 RECRUITING
AntibodyAkeso-drivenPhase 2

cadonilimab (cadonilimab)

Metastatic HER2 Positive Gastroesophageal Junction Cancer · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#인기#항체+5
임상시험 65상태 RECRUITING
AntibodyAkesogovitecan), and chimeric an…Phase 2

Ivonescimab (Ivonescimab)

Advanced Microsatellite Stable Colorectal Carcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma · HER2

#HER2#Antibody#Phase2#인기#항체+5
임상시험 62상태 RECRUITING
AntibodyRocheDM1Phase 2

trastuzumab (Herceptin, Pertuzumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#인기#항체+5
효능 ORR 88.6%임상시험 58상태 RECRUITING
AntibodyRochederuxtecan alone or followe…Phase 3

trastuzumab (Herceptin, Paclitaxel + Trastuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 80%임상시험 57상태 RECRUITING
AntibodyJazz Pharmaceuticalsderuxtecan, telisotuzumab v…Phase 2

Zanidatamab (ZW25, ZW25 (Zanidatamab))

HER2+/HR+ Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+5
효능 ORR 33%임상시험 33상태 ACTIVE
AntibodyQuantumLeap Healthcare Collabor…Phase 2

AMG 479 (AMG 479, Ganitumab, AMG 479 (Ganitumab) plus Metformin)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+5
효능 ORR 27%임상시험 30상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, HER2, pyrotinib + pertuzumab/trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 30상태 RECRUITING
AntibodystaleJazz PharmaceuticalsPhase 3

Zanidatamab (Zanidatamab)

HER2-positive Breast Cancer; Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+4
효능 ORR 34%임상시험 30상태 RECRUITING
AntibodystaleZhiyong YuPhase 2

Inetetamab (Inetetamab)

Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 26상태 ACTIVE
AntibodystaleRegeneronPhase 2

Cemiplimab plus REGN3767 (Cemiplimab plus REGN3767)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 23상태 RECRUITING
AntibodystaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
효능 ORR 67%임상시험 17상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Tucatinib plus trastuzumab and pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 11.5%임상시험 15상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 3.2%임상시험 4상태 RECRUITING
AntibodystaleRegeneronPhase 2

VV1 + Cemiplimab (VV1 + Cemiplimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 4상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, AMG 386 and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 2상태 RECRUITING
AntibodystaleRochePhase 3

HLX87 + Pertuzumab (HLX87 + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+3
임상시험 2상태 RECRUITING

1 / 4 페이지

← 이전다음 →